Brief: Entera Bio Regains Compliance With Nasdaq Listing Requirements
23/03/2023 14:24
March 23 (Reuters) - Entera Bio Ltd 5DT.F :
* ENTERA BIO REGAINS COMPLIANCE WITH NASDAQ LISTING
REQUIREMENTS
Source text for Eikon: ID:nGNX6slp0l
Further company coverage: 5DT.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement